These results suggest that even though the IL-32 promoter SNP does not have an effect on DAS28 scores, there might be a role for the genetic polymorphism in the promoter region of IL-32 in the prediction of clinical response to anti-TNFα treatment in RA patients also taking into account the observed influence on the production of pro-inflammatory cytokines in these patients. Here, IL32 is linked to rheumatoid arthritis.